Loading
Life sciences · Journal article
The Prostate · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Background Racial disparities in prostate cancer (PCa) survival are inconsistently reported. Methods We evaluated long‐term survival in 976 men from the NCI–Maryland PCa case‐control study, stratified by disease stage. Results There were no survival differences observed between African American (AA) and European American (EA) men with Stage 1 or 2 disease. In contrast, AA men with Stage 3 or 4 PCa experienced significantly higher prostate cancer‐specific and all‐cause mortality in equal‐access Veterans Affairs (VA) and non‐VA settings. Adjustment for baseline prostate‐specific antigen (PSA) level, Gleason score, and treatment modalities attenuated but did not eliminate these differences. Conclusions Disparate survival outcomes for AA men with PCa emerge mainly at Stage 3 or 4 diagnosis, emphasizing the importance of early detection for these men. Notably, AA patients with advanced‐stage disease were more likely to receive hormone therapy alone, a treatment pattern that may contribute to racial disparities in PCa survival.